From the Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh.
Department of Nephrology, Fortis Hospital, Mohali.
Clin Nucl Med. 2022 Jun 1;47(6):e466-e467. doi: 10.1097/RLU.0000000000004149. Epub 2022 Mar 30.
177Lu-PSMA-617 radioligand therapy (RLT) has evolved as a suitable alternative to existing therapeutic options in patients with metastatic castration-resistant prostate cancer. With the emergence of α-emitters such as 225Ac, the efficacy of PSMA-RLT has further improved. Xerostomia and myelosuppression are common early treatment-emergent adverse events in patients receiving this therapy; however, data on long-term toxicity are relatively scarce. In this report, we describe a 76-year-old man with metastatic castration-resistant prostate cancer, who after having an initial excellent response to 2 cycles of 225Ac-PSMA-617 RLT, developed delayed nephrotoxicity in the form of tubulointerstitial nephritis.
177Lu-PSMA-617 放射性配体治疗 (RLT) 已成为转移性去势抵抗性前列腺癌患者现有治疗选择的合适替代方案。随着 225Ac 等 α 发射器的出现，PSMA-RLT 的疗效进一步提高。口干和骨髓抑制是接受这种治疗的患者常见的早期治疗出现的不良事件；然而，关于长期毒性的数据相对较少。在本报告中，我们描述了一名 76 岁的转移性去势抵抗性前列腺癌患者，他在接受 2 个周期的 225Ac-PSMA-617 RLT 初始治疗后反应良好，随后出现了以肾小管间质性肾炎为表现的延迟性肾毒性。
